![](https://endpts.com/wp-content/uploads/2018/05/will-west-cellcentric-tile.jpg)
Cambridge spinout CellCentric gets $26M for single-asset epigenetics approach to prostate cancer
Can a biotech developing an epigenetics drug squeeze into J&J and Pfizer’s turf fight in prostate cancer? Cambridge, UK-based CellCentric now has $26 million to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.